Areteia is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma.
Areteia's mission is to give people with eosinophilic asthma control of their disease—and their lives.
Areteia was created in 2022 by Population Health Partners and Knopp Biosciences. The company is headquartered in Research Triangle Park, North Carolina.
Areteia’s lead drug candidate is dexpramipexole, a first-in-class oral medicine that inhibits the maturation of eosinophils before they can cause damage.
Areteia has initiated a late-stage development including Phase 3 clinical trials of dexpramipexole in partnership with Population Health Partners’ development unit, Validae Health.
Areteia has raised $350M in Series A funding on Jul 12, 2022. The round was led by Bain Capital Life Sciences, with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners.